- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02214901
Safety, Tolerability and Pharmacokinetics of BIBW 2948 BS in Healthy Male Volunteers
August 12, 2014 updated by: Boehringer Ingelheim
A Randomised, Double-blind, Placebo-controlled (Within Dose Groups) Study to Evaluate Safety, Tolerability and Pharmacokinetics of Single Rising Inhaled Doses BIBW 2948 BS (0.75 to 150 mg Inhalation Powder, Hard Capsule for HandiHaler®) in Healthy Male Volunteers
Study to investigate safety, tolerability, and pharmacokinetics of BIBW 2948 BS
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
91
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years to 50 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
Healthy males based on a complete medical history, including physical examination, vital signs (BP, PR), 12-lead ECG, and clinical laboratory tests:
- No finding deviating from normal and of clinical relevance
- No evidence of a clinically relevant concomitant disease
- Aged between ≥21 and ≤50 years
- BMI (Body Mass Index) between ≥18.5 and ≤30 kg/m2
- Provision of written informed consent signed and dated prior to admission to the study in accordance with good clinical practice (GCP) and local legislation
Exclusion Criteria:
- Any finding during the medical examination (including BP, PR and ECG) deviating from normal and of clinical relevance
- Any evidence of a clinically relevant concomitant disease
- Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- History of relevant orthostatic hypotension, fainting spells or blackouts
- Chronic or relevant acute infections
- History of relevant allergy/hypersensitivity (including allergy to the drug or its excipients)
- Intake of drugs with a long half-life (>24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial
- Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial
- Participation in another trial with an investigational drug within two months prior to administration or during the trial
- Smoker (>10 cigarettes or >3 cigars or >3 pipes/day)
- Inability to refrain from smoking on trial days
- Alcohol abuse (more than 60 g/day)
- Drug abuse
- Blood donation (more than 100 mL within four weeks prior to administration or during the trial)
- Excessive physical activities (within one week prior to administration or during the trial)
- Any laboratory value outside the reference range that is of clinical relevance
- Inability to comply with dietary regimen of study centre
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
|
Experimental: BIBW 2948 BS in single rising doses
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes from baseline in vital signs (blood pressure, pulse rate, respiratory rate, orthostasis test, oral body temperature)
Time Frame: Up to 8 days after start of treatment
|
Up to 8 days after start of treatment
|
|
Changes from baseline in clinical laboratory tests
Time Frame: Up to 8 days after start of treatment
|
Up to 8 days after start of treatment
|
|
Changes from baseline in 12-lead electrocardiogram (ECG)
Time Frame: Up to 8 days after start of treatment
|
Up to 8 days after start of treatment
|
|
Number of patients with adverse events
Time Frame: Up to day 29
|
Up to day 29
|
|
Changes from baseline in airway resistance (Raw)
Time Frame: Pre-dose, up to 24 hours after start of treatment
|
measured via plethysmography
|
Pre-dose, up to 24 hours after start of treatment
|
Assessment of tolerability by investigator, a 4-point scale
Time Frame: Up to 8 days after start of treatment
|
Up to 8 days after start of treatment
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Area under the concentration-time curve of the analytes in plasma at different time points (AUCt1-t2)
Time Frame: Pre-dose, up to 48 hours after start of treatment
|
Pre-dose, up to 48 hours after start of treatment
|
Maximum concentration of BIBW 3056 ZW in plasma (Cmax)
Time Frame: Pre-dose, up to 48 hours after start of treatment
|
Pre-dose, up to 48 hours after start of treatment
|
Time from dosing to maximum concentration of the analytes in plasma (tmax)
Time Frame: Pre-dose, up to 48 hours after start of treatment
|
Pre-dose, up to 48 hours after start of treatment
|
Amount of BIBW 3056 ZW eliminated in urine at different time points (Aet1-t2)
Time Frame: Pre-dose, up to 48 hours after start of treatment
|
Pre-dose, up to 48 hours after start of treatment
|
Fraction of BIBW 3065 ZW eliminated in urine at different time points (fet1-t2)
Time Frame: Pre-dose, up to 48 hours after start of treatment
|
Pre-dose, up to 48 hours after start of treatment
|
Renal clearance of BIBW 3056 ZW from 0 to 24 hours (CLR,0-24)
Time Frame: Pre-dose, up to 48 hours after start of treatment
|
Pre-dose, up to 48 hours after start of treatment
|
Terminal rate constant of BIBW 3056 ZW in plasma (λz)
Time Frame: Pre-dose, up to 48 hours after start of treatment
|
Pre-dose, up to 48 hours after start of treatment
|
Terminal half life of BIBW 3056 ZW in plasma (t½)
Time Frame: Pre-dose, up to 48 hours after start of treatment
|
Pre-dose, up to 48 hours after start of treatment
|
Mean residence time of BIBW 3056 ZW in the body after inhalation (MRTih)
Time Frame: Pre-dose, up to 48 hours after start of treatment
|
Pre-dose, up to 48 hours after start of treatment
|
Apparent clearance of BIBW 3056 ZW in the plasma after extravascular administration (CL/F)
Time Frame: Pre-dose, up to 48 hours after start of treatment
|
Pre-dose, up to 48 hours after start of treatment
|
Apparent volume of distribution of BIBW 3056 ZW during the terminal phase λz following an extravascular dose (Vz/F)
Time Frame: Pre-dose, up to 48 hours after start of treatment
|
Pre-dose, up to 48 hours after start of treatment
|
The percentage of the AUC 0-∞ that is obtained by extrapolation (%AUCtz-∞)
Time Frame: Pre-dose, up to 48 hours after start of treatment
|
Pre-dose, up to 48 hours after start of treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2005
Primary Completion (Actual)
July 1, 2005
Study Registration Dates
First Submitted
August 12, 2014
First Submitted That Met QC Criteria
August 12, 2014
First Posted (Estimate)
August 13, 2014
Study Record Updates
Last Update Posted (Estimate)
August 13, 2014
Last Update Submitted That Met QC Criteria
August 12, 2014
Last Verified
August 1, 2014
More Information
Terms related to this study
Other Study ID Numbers
- 1219.1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States